Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.9 (
glucose-6-phosphatase
)
3,081
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glycogen storage disease type 1 (
GSD
1) results from deficiency of the microsomal multicomponent
glucose-6-phosphatase
system. Malfunction of the catalytic subunit characterises
GSD
1a.
GSD
1b and
GSD
1c are characterised by defective microsomal glucose-6-phosphate or pyrophosphate/phosphate transport, respectively. Recently, a gene encoding a microsomal transporter protein has been found to be mutated in
GSD
1b and 1c patients. Here, we report the genomic sequence of the transporter gene and the detection of a homozygous 2-bp deletion (1211delCT) and a homozygous donor splice site mutation (317+1G-->T) in two
GSD
1c patients, confirming that
GSD
1c is allelic to
GSD
1b.
...
PMID:Molecular diagnosis of type 1c glycogen storage disease. 1032 54
Glycogen storage diseases type 1 (
GSD
1) are a group of autosomal recessive disorders characterized by impairment of terminal steps of glycogenolysis and gluconeogenesis. Mutations of the
glucose-6-phosphatase
gene are responsible for the most frequent form of
GSD
1, the subtype 1a, while mutations of the glucose-6-phosphate transporter gene (G6PT) have recently been shown to cause the non 1a forms of
GSD
, namely the 1b and 1c subtypes. Here, we report on the analysis by single-stranded conformation polymorphism (SSCP) and/or DNA sequencing of the exons of the G6PT in 14 patients diagnosed either as affected by the
GSD
1b or 1c subtypes. Mutations in the G6PT gene were found in all patients. Four of the detected mutations were novel mutations, while the others were previously described. Our results confirm that the
GSD
1b and 1c forms are due to mutations in the same gene, i.e. the G6PT gene. We also show that the same kind of mutation can be associated or not with evident clinical complications such as neutrophil impairment. Since no correlation between the type and position of the mutation and the severity of the disease was found, other unknown factors may cause the expression of symptoms, such as neutropenia, which dramatically influence the severity of the disease.
...
PMID:Mutations in the glucose-6-phosphate transporter (G6PT) gene in patients with glycogen storage diseases type 1b and 1c. 1051 30
Glycogen storage disease type 1 (GSD-1) is a group of autosomal recessive disorders caused by deficiencies in
glucose-6-phosphatase
(
G6Pase
) and the associated substrate/product transporters. Molecular genetic studies have demonstrated that
GSD
-1a and
GSD
-1b are caused by mutations in the
G6Pase
enzyme and a glucose-6-phosphate transporter (G6PT), respectively. While kinetic studies of
G6Pase
catalysis predict that the index
GSD
-1c patient is deficient in a pyrophosphate/phosphate transporter, the existence of a separate locus for
GSD
-1c remains unclear. We have previously shown that the
G6Pase
gene of the index
GSD
-1c patient is intact; we now show that the G6PT gene of this patient is normal, strongly suggesting the existence of a distinct
GSD
-1c locus.
...
PMID:Type-1c glycogen storage disease is not caused by mutations in the glucose-6-phosphate transporter gene. 1059 22
Glycogen storage disease type 1a (GSD-1a), characterized by hypoglycemia, liver and kidney enlargement, growth retardation, hyperlipidemia, and hyperuricemia, is caused by a deficiency in
glucose-6-phosphatase
(
G6Pase
), a key enzyme in glucose homeostasis. To evaluate the feasibility of gene replacement therapy for
GSD
-1a, we have infused adenoviral vector containing the murine
G6Pase
gene (Ad-mG6Pase) into
G6Pase
-deficient (
G6Pase
(-/-)) mice that manifest symptoms characteristic of human
GSD
-1a. Whereas <15% of
G6Pase
(-/-) mice under glucose therapy survived weaning, a 100% survival rate was achieved when
G6Pase
(-/-) mice were infused with Ad-mG6Pase, 90% of which lived to 3 months of age. Hepatic
G6Pase
activity in Ad-mG6Pase-infused mice was restored to 19% of that in
G6Pase
(+/+) mice at 7-14 days post-infusion; the activity persisted for at least 70 days. Ad-mG6Pase infusion also greatly improved growth of
G6Pase
(-/-) mice and normalized plasma glucose, cholesterol, triglyceride, and uric acid profiles. Furthermore, liver and kidney enlargement was less pronounced with near-normal levels of glycogen depositions in both organs. Our data demonstrate that a single administration of a recombinant adenoviral vector can alleviate the pathological manifestations of
GSD
-1a in mice, suggesting that this disorder in humans can potentially be corrected by gene therapy.
...
PMID:Correction of glycogen storage disease type 1a in a mouse model by gene therapy. 1062 14
Glycogen storage disease type Ia (GSD-Ia) is an autosomal recessive disorder of glycogen metabolism caused by a deficiency of
glucose-6-phosphatase
(
G6Pase
) that is expressed in the liver, kidney, and intestinal mucosa. Clinical manifestations include short stature, hepatomegaly, hypoglycemia, hyperuricemia, and lactic acidemia. To elucidate a spectrum of the
G6Pase
gene mutations and their frequencies, we analyzed mutations in 51 unrelated Japanese patients with
GSD
-Ia. The most prevalent mutation was g727t, accounting for 88 of 102 mutant alleles examined, followed by R170X mutation, which accounted for 6 mutant alleles, and R83H mutation which was observed in 3 mutant alleles. In addition, 3 different, novel mutations, IVS1-1g<a, Gly122-to-Asp (G122D) and His179-to-Pro (H179P), were identified. We were able to detect "ectopically" transcribed
G6Pase
-mRNA in Epstein-Barr virus-transformed lymphoblastoid cells and observed aberrant mRNA splicing associated with the g727t and IVS1-1g<a mutations. To our knowledge, this is the first report that ectopic expression can be utilized for the characterization of
GSD
-Ia mutations. Our findings suggest that a screening for the g727t, R170X, and R83H mutations by simple DNA-based diagnostic methods can detect 95% of the
G6Pase
mutant alleles in Japanese patients with
GSD
-Ia, and remaining mutations can be identified and characterized by the direct sequencing of genomic DNA and/or the analysis of ectopically expressed mRNA. The noninvasive molecular diagnosis for
GSD
-Ia may ultimately replace the conventional means of enzymatic diagnosis that requires liver biopsy.
...
PMID:Glycogen storage disease type Ia: molecular diagnosis of 51 Japanese patients and characterization of splicing mutations by analysis of ectopically transcribed mRNA from lymphoblastoid cells. 1074 7
Glycogen storage disease type Ia (GSD-Ia) is an autosomal recessive disorder of glycogen metabolism caused by
glucose-6-phosphatase
(
G6Pase
) deficiency. It is characterized by short stature, hepatomegaly, hypoglycemia, hyperuricemia, and lactic acidemia. Various mutations have been reported in the
G6Pase
gene (G6PC). However, in Japanese patients, a g727t substitution was found to be the major cause of
GSD
-Ia, accounting for 20 of 22 mutant alleles [Kajihara et al., 1995], and no other mutations have been found in this population. We analyzed four Japanese
GSD
-Ia patients and identified three other mutations in addition to the g727t. They included two missense mutations (R83H and P257L) and one nonsense mutation (R170X). Each of the three mutations exhibited markedly decreased
G6Pase
activity when expressed in COS7 cells. A patient homozygous for R170X showed multiple episodes of profound hypoglycemia associated with convulsions, while P257L was associated with a mild clinical phenotype. The presence of R170X in three unrelated families may implicate that it is another important mutation in the etiology of
GSD
-Ia in Japanese patients. Thus, the detection of non-g727t mutations is also important in establishing the DNA-based diagnosis of
GSD
-Ia in this population.
...
PMID:Heterogeneous mutations in the glucose-6-phosphatase gene in Japanese patients with glycogen storage disease type Ia. 1079 30
Mutations in the
glucose-6-phosphatase
(
G6Pase
) gene are responsible for glycogen storage disease type Ia (
GSD
Ia). A study of the molecular basis of
GSD
Ia was carried out in 12 Czech and Slovak
GSD
Ia patients from 10 unrelated families. Mutation analysis was performed for the entire coding region of
G6Pase
gene using DGGE, sequencing and PCR/digestion. With the strategy used, all mutant alleles were identified in this study. Three novel mutations (K76N, V166A and 540del5), six previously described mutations (W77R, R83C, G188R, R295C, Q347X and 158delC) and one known polymorphism (1176T-->C) were detected. The most common mutation identified was R83C, accounting for 8 out of 20 (40%) mutant alleles. The K76N mutation was found in a Gypsy family: two siblings with
GSD
Ia were homozygous for this mutation. These findings expand our knowledge of mutations responsible for glycogen storage disease type Ia.
...
PMID:Identification of mutations in the glucose-6-phosphatase gene in Czech and Slovak patients with glycogen storage disease type ia, including novel mutations K76N, V166A and 540del5. 1087 13
Glycogen storage disease type Ia (
GSD
Ia) is caused by a deficiency of
glucose-6-phosphatase
(
G6Pase
) activity. Eighteen
GSD
Ia families were studied for
G6Pase
gene mutations. Thirty-two mutations were found in 36
GSD
Ia chromosomes: 16 were 727 G-->T (44.44%); 13 were R83H (327 G-->T; 36.11%); 1 was 341delG; 1 was 933insAA; and 1 was 793 G-->T. The 727 G-->T and R83H mutations together accounted for 80.56% (29/36) of the
GSD
Ia chromosomes. These two mutations were easily examined by polymerase chain reaction-based methods, and the prenatal diagnosis of a non-affected fetus was successfully made. The 727 G-->T mutation is the predominant mutation in Japanese
GSD
Ia patients, but is rarely seen in Western counties. The 727 G-->T mutation is also the most prevalent mutation in Taiwan Chinese, although the incidence is not as high as in Japan.
...
PMID:Glucose-6-phosphatase gene mutations in Taiwan Chinese patients with glycogen storage disease type Ia. 1094 47
Glycogen storage disease type 1a (
GSD
1a) is caused by a deficiency in microsomal
glucose-6-phosphatase
(
G6Pase
). A variant (
GSD
1b) is caused by a defect in the transport of glucose-6-phosphate (G6P) into the microsome and is associated with chronic neutropenia and neutrophil dysfunction. Mutually exclusive mutations in the
G6Pase
gene and the G6P transport gene establish
GSD
la and
GSD
1b as independent molecular processes and are consistent with a multicomponent translocase catalytic model. A modified translocase/catalytic unit model based on biochemical data in a
G6Pase
knockout mouse has also been proposed for
G6Pase
catalysis. This model suggests coupling of
G6Pase
activity and G6P transport. A 5-mo-old girl with hypoglycemia, hepatomegaly, and lactic acidemia was diagnosed with
GSD
1a. She also developed neutropenia, neutrophil dysfunction, and recurrent infections characteristic of
GSD
1b. Homozygous G188R mutations of the
G6Pase
gene were identified, but no mutations in the G6P translocase gene were found. We have subsequently identified a sibling and two unrelated patients with similar genotypic/phenotypic characteristics. The unusual association of neutrophil abnormalities in patients with homozygous G188R mutations in the
G6Pase
gene supports a modified translocase/catalytic unit model.
...
PMID:Glucose-6-phosphatase mutation G188R confers an atypical glycogen storage disease type 1b phenotype. 1096 Apr 98
Forty-eight patients with glycogen storage disease type Ia (
GSD
Ia) were studied. Using a combination of single-strand conformation polymorphism (SSCP) analysis, restriction enzyme digestion and direct sequencing, we were able to identify 93/96 mutant alleles, comprising 23 different mutations in the
glucose-6-phosphatase
gene (G6PC). Among these, 7 are novel mutations of G6PC: M5R, T111I, A241T, C270R, F322L, and two deletions, 793delG and 872delC, resulting in the same mutation at the amino acid level, fs300Ter (300X).
...
PMID:Genetic heterogeneity of glycogen storage disease type Ia in France: a study of 48 patients. 1105 3
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>